You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 128 No. 2, February 1992 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  STUDIES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (40)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

The Protective Effect of Vitamin E on the Hemolysis Associated With Dapsone Treatment in Patients With Dermatitis Herpetiformis

Ronald Prussick, MD; Mahmoud A. M. Ali, MD, PhD; Donald Rosenthal, MD; Gordon Guyatt, MD

Arch Dermatol. 1992;128(2):210-213.


Abstract



• Objective.—
This study looked at whether oral vitamin C and vitamin E would protect the erythrocyte from oxidant damage caused by dapsone in patients with dermatitis herpetiformis.

Design.—
Fifteen consecutive patients with dermatitis herpetiformis taking dapsone therapy received, in addition, 800 U/d of vitamin E for 4 weeks; then 1000 mg of vitamin C per day for 4 weeks, and, finally, combined vitamin E and vitamin C therapy for 4 weeks. Hemolysis indexes were assessed at baseline and after each 4-week period.

Results.—
Statistical analysis of the results suggests that oral administration of 800 units of vitamin E daily for 4 weeks confers partial protective effect against dapsone-induced hemolysis in patients with dermatitis herpetiformis.

Conclusion.—
Partial protection against dapsone-induced hemolysis by orally administered vitamin E, if confirmed as being clinically relevant by further trials, may allow clinicians to continue dapsone therapy orally in patients who develop significant hemolysis. Prophylactic vitamin E to minimize potential hemolysis at the initiation of dapsone therapy may also be appropriate.

(Arch Dermatol. 1992;128:210-213)



Author Affiliations



From the Department of Medicine, Division of Dermatology, University of Toronto, Ontario (Dr Prussick); Department of Pathology, St Joseph's Hospital, Hamilton, Ontario (Dr Ali); and Departments of Pathology (Dr Ali), Medicine, Division of Dermatology, Faculty of Health Sciences (Dr Rosenthal), and Medicine and Clinical Epidemiology and Biostatistics (Dr Guyatt), McMaster University, Hamilton, Ontario.


Footnotes



Accepted for publication September 25, 1991.

Reprints not available.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Unexpected Cause of Anemia in a 45-Year-Old Patient With Acute Lymphoblastic Leukemia
Pendse et al.
Lab Med 2010;41:645-648.
FULL TEXT  

Pharmacokinetic Profiles in Rats After Intravenous, Oral, or Dermal Administration of Dapsone
Helton et al.
Drug Metab. Dispos. 2000;28:925-929.
ABSTRACT | FULL TEXT  

Comparison of the Metabolism and Toxicity of Dapsone in Rat, Mouse and Man
Tingle et al.
J. Pharmacol. Exp. Ther. 1997;283:817-823.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1992 American Medical Association. All Rights Reserved.